Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Geron announces five ASH 2025 presentations highlighting RYTELO® efficacy in myeloid malignancies.
Faron announces two Bexmarilimab abstracts accepted at ASH 2025, including oral.
Rigel to present one oral and four posters at ASH 2025.
LDLRAD4 identified as diagnostic and prognostic biomarker in myelodysplastic syndromes.
DelveInsight releases 2025 report on emerging therapies in myelodysplastic syndrome.
Geron announces five ASH 2025 presentations showcasing RYTELO® in myeloid malignancies.
ASXL1 truncation and SRSF2 mutation promote leukemogenesis through immune reprogramming.
Rigel to present one oral and four posters at ASH 2025.
Geron to present five ASH 2025 studies on RYTELO® in myeloid malignancies.
Geron to showcase five ASH 2025 presentations on RYTELO® in myeloid cancers.
Faron announces two Bexmarilimab abstracts accepted at ASH 2025, including oral presentation.
Geron announces five ASH 2025 presentations showcasing RYTELO® efficacy in myeloid malignancies.
Emerging therapies drive growth in lower-risk MDS market, led by top pharma companies.
Sylvester researchers deliver over 35 oral presentations at ASH 2025.
Servier showcases new data at ASH 2025, reinforcing hematology research commitment.
Halia Therapeutics to present Ofirnoflast NEK7 inhibitor data at ASH 2025.
Sylvester researchers deliver over 35 oral presentations at ASH 2025 meeting.
Taiho Oncology announces 14 presentations, including six orals, at ASH 67.
Azacitidine treatment linked to unexpected development of arthropathy beyond bone marrow.
Sylvester researchers contribute over 100 poster presentations at ASH 2025 in Orlando.
Halia Therapeutics presents novel NEK7 inhibitor Ofirnoflast at ASH 2025.
Human iPSCs show SETBP1 influences chromatin modifications and gene regulation.
Myelodysplastic syndrome therapeutics market in 7MM projected to grow by 2034, DelveInsight.
Taiho Oncology to present 14 studies, including six oral presentations, at ASH 67.
Preview of ASH 2025 posters from Sylvester Comprehensive Cancer Center.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
HSCT Shows Promising Effectiveness in Treating Transformed Severe Aplastic Anemia
Florida Cancer Specialists Studies Lower-Risk MDS Treatment Response Using Real-World Data
US Myelodysplastic Syndrome Market Growth Driven by Pipeline Drugs, Aging Population
Low Utilization and Disparities in Hypomethylating Agent Use for MDS
Myeloid sarcoma mimicking intramuscular abscesses in myelodysplastic syndrome patient
Dr. Daver discusses ongoing gaps in treating relapsed, high-risk MDS
Myelodysplastic syndrome drugs market projected at $2,057.7M by 2032, growing 7.9% CAGR
Who requires a bone marrow transplant? Signs and related conditions explained
Orca Bio’s BLA for Orca-T receives FDA acceptance, priority review
Marker Therapeutics begins Phase 1 RAPID trial for AML, MDS treatment
Outcomes of elderly patients with TP53-mutated myeloid neoplasms analyzed
Managing side effects for MDS patients receiving Imetelstat treatment.
Talha Badar discusses current MDS prognostication models for DDX41 mutation patients.
Rigel enrolls first patient in R289 MDS dose expansion phase 1b study.
Orca Bio Orca-T BLA accepted, FDA grants Priority Review for hematological malignancies.
Poor outcomes for older patients with TP53-mutated myeloid neoplasms.
Dr. Ashwin Kishtagari selects his top four picks from SOHO 2025.
Faron data reveal stronger Bexmarilimab response in high-risk blood cancer.
Rigel enrolls first patient in Phase 1b R289 lower-risk MDS study.
Marker Therapeutics launches Phase 1 RAPID trial for AML, MDS treatment.
Mikkael Sekeres, M.D., M.S., elected to American Society of Hematology executive committee.
Rigel enrolls first patient in Phase 1b R289 lower-risk MDS study.
Venetoclax with Azacitidine Versus Placebo in Treatment-Naïve High-Risk MDS
Talha Badar: Prognostic Models for MDS Patients Harboring DDX41 Mutations
Myelodysplastic syndrome drugs market projected at USD 2,057.
7 million by 2032.Outcomes of older patients with TP53-mutated myeloid neoplasms studied.
Rigel Pharmaceuticals enrolls first patient in Phase 1b R289 MDS study.
Chordia Therapeutics’ CTX-712 study shows breakthrough potential in AML and HR-MDS.
Bristol Myers Squibb’s ELEMENT-MDS trial shows transformative potential in anemia treatment.
Bristol Myers Squibb’s ELEMENT-MDS trial shows groundbreaking potential in anemia treatment.
Agios Pharmaceuticals reports promising tebapivat study results for anemia in LR-MDS.
Nathan Pennell honors the remarkable dedication of the myelodysplastic syndromes community.
Large-scale NGS study reveals diagnostic importance of SH2B3 mutations in leukemia.
FDA grants orphan drug designation to Ofirnoflast for MDS patients.
Faron Pharma’s BEXMAB trial demonstrates breakthrough results in MDS treatment.
Phase 2 trial studies G-CSF with venetoclax and azacitidine in AML.
SH2B3 mutations show diagnostic significance in myeloid malignancies and leukemia.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
2025 MDS pipeline analysis by DelveInsight features major pharmaceutical companies.
Relapsed or refractory myelodysplastic syndrome market projected at \$6.1 billion by 2034.Bone marrow
failure market grows due to rising aplastic anemia, MDS cases.
Conditioning intensity in MDS patients ≥50 undergoing allo-HCT studied by EBMT.
Research shows cancer itself, not only treatments, accelerates aging in patients.
Biosplice doses first patient in NCI trial of Cirtuvivint for AML, MDS.
Evaluating the evolution of diagnostic criteria for Myelodysplastic Syndrome.
Venetoclax does not improve survival outcomes in high-risk MDS.
Venclexta combined with Azacitidine fails to improve MDS survival outcomes.
Impact of discordant revised versus molecular prognostic scoring in myelodysplastic syndrome.
Combination therapy fails to achieve survival improvement in myelodysplastic syndromes trial.
Robot-assisted hysterectomy reveals platelet dysfunction in myelodysplastic syndrome patient postope
Do knowledge gaps contribute to inadequate HMA-based care for MDS patients?
Lupin receives US FDA approval for generic Lenalidomide in multiple strengths.
Is HMA therapy for MDS in the United States fully optimized?
Exploring the connection between myelodysplastic syndromes and autoimmune disorders.
Florida Cancer Specialists studies lower-risk MDS patient responses using proprietary real-world dat
Phase 3 trial investigates innovative treatment strategy for myelodysplastic syndrome.
Clonal evolution and apoptosis resistance in MDS and AML under treatment.
2025 Relapsed/Refractory MDS Pipeline: Innovations from 5+ Global Companies Highlighted.
MDS treatment progresses with targeted therapies and improved anemia management strategies.
Long-term efficacy and safety results from Phase 3 COMMANDS trial updated.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Gene clustering reveals distinct patterns of immune dysregulation in MDS.
ASH Insights: Identifying the Best Treatment for High-Risk Myelodysplastic Syndromes
Data Reveal Disparities in Hypomethylating Agent Use Among MDS Populations
FDA Approves Roxadustat Phase 3 Trial for Anemia in MDS
Blood Cell Patterns Linked to Poor Response to Venetoclax Treatment
FDA Backs Progression of Roxadustat Trial for Anemia in MDS
Registrational Trial Launches for Bexmarilimab in Frontline High-Risk MDS
Faron Pharmaceuticals Accelerates Bexmarilimab for HR-MDS, Boosting Shareholder Value
Global Phase 3 Trial of Lisaftoclax Approved for Higher-Risk MDS
Ascentage Pharma Starts Patient Enrollment in FDA, EMA-Approved GLORA-4 Trial
Ascentage Pharma Announces FDA, EMA-Cleared Global Phase III Lisaftoclax Study
HMAs Are Underused in Older, Female, and Non-White Myelodysplastic Syndrome Patients
Limited Use of Hypomethylating Agents Observed in Myelodysplastic Syndrome Patients
11th Annual EWOG-MDS/SAA Symposium on Myelodysplastic Syndromes and Severe Aplastic Anemia
Hematologic Malignancies Characterized Across the Spectrum in Li-Fraumeni Syndrome
Bexmarilimab Combined with Azacitidine Demonstrates Activity in High-Risk Myelodysplastic Syndrome

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Real-World Data Backs Effectiveness of Luspatercept in Lower-Risk MDS
Dr. Zeidan Discusses BEXMAB Study Findings and Impact on MDS Care
Luspatercept outcomes in MDS remain consistent regardless of mutational profile.
CEBPA mutation drives progression from myelodysplastic syndromes to AML.
MDS Market Report 2025–2035: Pipeline, Drug Sales, Regional Outlook.
Zinc-Induced Copper Deficiency Mimics Myelodysplastic Syndrome: A Hematologic Twist
Myelodysplastic Syndrome Pipeline 2025: 150+ Therapies Transforming Blood Cancer
COMMANDS Trial Explores Luspatercept’s Efficacy in ESA-Naive Lower-Risk MDS
Luspatercept Market Grows with Anemia Advances in MDS and Beta-Thalassemia.
High-Risk MDS Market Grows with Focus on Survival, New Therapies.
Lenalidomide Market Thrives on Demand for Targeted Low-Risk MDS Therapies.
Europe MDS Market Grows with Diagnostics, Novel Therapies from 2025-2032.
2025 MDS Trials: Approvals, Treatments, Mechanisms, and Key Companies.
Stem Cell Transplant Market Grows with Curative Therapies, Better Matching.
What truly helped me persevere through fifteen challenging years with cancer.
Luspatercept in frontline MDS treatment: real-world data and experience.
IHC testing could complement NGS for early detection of TP53-mutant MDS and AML.
Myelodysplastic syndrome trials, companies, therapies, pipeline analysis, and treatment strategies o
BTX A51 shows good tolerability and manageable safety in R/R AML, MDS.
Luspatercept in MDS management: remaining data and clinical experience gaps.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:Dr. Catherine Lai: Leukemia, MDS, MPN, and Transplant Research Updates.
Bexmarilimab demonstrates survival benefit in relapsed/refractory myelodysplastic syndromes patients
Dr. Zeidan discusses BEXMAB study results’ impact on MDS care.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Dr. Naval Daver Reveals Game-Changing MDS Breakthroughs and Future Plans
Pushing Boundaries in Myelodysplastic Syndromes: Innovations Improving Patient Outcomes

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
DS Experts Review Long-Term Results from the COMMANDS Clinical Trial
Experts Forecast Future Trends in MDS Management and Treatment Strategies
How Do Hemoglobin Levels Impact Quality of Life in MDS?
Dr. Nicole Grieselhuber on Advancing Therapies for High-Risk MDS Treatment

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
‍Navigating ESA failure in myelodysplastic syndromes and exploring alternative treatments.
Noteworthy developments in 2024 breaking ground in myelodysplastic syndromes (MDS).
Expert perspectives on ESA treatment outcomes in lower-risk myelodysplastic syndromes.
Key takeaways from the COMMANDS trial for optimizing MDS management strategies.
Esther Olivia reports COMMANDS trial HRQoL results unveiled at ASH 2024.
Impact of Hypomethylating Agents Response and Time-to-Transplant on MDS Outcomes
Dr. Zeidan discusses Luspatercept in MDS and anemia in COMMANDS Trial.

‍The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Exploring the impact of luspatercept on cell lineages in MDS.
Dr. Jamie Koprivnikar discusses the COMMANDS trial and luspatercept dosing.
How is the MDS Patient Experience Assessed?
Does Luspatercept Alleviate Healthcare System Resource Utilization in MDS?
How Do Prognostic Models Influence Treatment Decisions in MDS?
Panel Discusses COMMANDS Trial Data in Lower-Risk MDS.
Panel discusses imetelstat as a treatment for lower-risk MDS patients.
Identifying patients who should receive luspatercept for effective treatment outcomes.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Guillermo Garcia-Manero, MD, Discusses Recent Advances in Low-Risk MDS
Dr. Chedid on Phase III COMMANDS Findings on MDS Anemia
Examining Current and Future Treatment Options for Patients with Low-Risk MDS.
What Does the Current Treatment Landscape for MDS Look Like?
Guillermo Garcia-Manero, MD, presents latest findings on luspatercept for MDS.
Valeria Santini, MD, discusses Novel Drugs for Low-Risk MDS Anemia.
What Key Themes Shape Recent Prognostication and Treatment of Lower-Risk MDS?
Essential Insights on Optimal Luspatercept Usage in Lower-Risk MDS
Dr. Swoboda Discusses the Significance of MDS World Awareness Day

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Comparing Treatment Options: Luspatercept vs. Erythropoiesis-Stimulating Agents (ESAs)
Clinical Benefits of Luspatercept Dose Titration: Evidence from Real-World Data
MCH Minute Unavailable
Approaches to Starting and Adjusting Luspatercept Dosing
Imetelstat Sustains Transfusion Independence in Low-Risk MDS
Allogeneic Hematopoietic Stem Cell Transplantation
Graft vs Host Disease (GVHD)
Hematopoietic Stem Cell Transplantation: How I Decide
Myelodysplastic Syndrome (MDS)
MDS: How I Intend to Use Imetelstat in My Practice
How I Treat Low Risk MDS
Recent Advances in Myelodysplastic Syndromes (MDS)

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org